From myocarditis to cardiomyopathy: Mechanisms of inflammation and cell death: Learning from the past for the future

Circulation

Volumn 99, Issue 8, 1999, Pages 1091-1100

  Kawai, Chuichi ^a  

^a NONE   (Japan)

Author keywords

Apoptosis; Cardiomyopathy; Immune system; Myocarditis; Viruses

Indexed keywords

CELL DEATH; GENE AMPLIFICATION; HEART DILATATION; HEART MUSCLE BIOPSY; HUMAN; IMMUNOMODULATION; INFLAMMATORY DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; VIRUS GENE; VIRUS MYOCARDITIS;

EID: 0033514987     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.99.8.1091     Document Type: Review

References (107)

1. Gore I, Saphir O. Myocarditis: a classification of 1402 cases. Am Heart J. 1947;34:827-830.
2. Kawai C. Idiopathic cardiomyopathy: a study on the infectious-immune theory as a cause of the disease. Jpn Circ J. 1971;35:765-770.
3. Kawai C, Matsumori A, Kitaura Y, Takatsu T. Viruses and the heart: viral myocarditis and cardiomyopathy. Prog Cardiol. 1978;7:141-162.
4. Woodruff JF. Viral myocarditis: a review. Am J Pathol. 1980;101: 425-483.
5. Gatmaitan BG, Chason JL, Lerner AM. Augmentation of the virulence of murine coxsackievirus B-3 myocardiopathy by exercise. J Exp Med. 1970;131:1121-1136.
6. Huber SA, Job LP, Auld KP. Influence of sex hormones on coxsackie B-3 virus infection in Balb/c mice. Cell Immunol. 1982;67:173-189.
7. Lyden DC, Huber SA. Aggravation of coxsackievirus, group B, type 3-induced myocarditis and increase in cellular immunity to myocyte antigens in pregnant Balb/c mice and animals treated with progesterone. Cell Immunol. 1984;87:462-472.
8. Lyden D, Olszewski J, Huber SA. Influence of sex hormones on coxsackie virus group B, type 3 induced myocarditis in Balb/c mice. Eur Heart J. 1987;8(suppl J):389-391.
9. Grodums EI, Dempster G. The age factor in experimental coxsackie B-3 infection. Can J Microbiol. 1959;5:595-604.
10. Grodums EI, Dempster G. Myocarditis in experimental coxsackie B-3 infection. Can J Microbiol. 1959;5:605-615.
11. Matsumori A, Kawai C. An animal model of congestive (dilated) cardiomyopathy: dilatation and hypertrophy of the heart in the chronic stage in DBA/2 mice with myocarditis caused by encephalomyocarditis virus. Circulation. 1982;66:355-360.
12. Kawai C, Sasayama S, Sakurai T, Matsumori A, Yui Y. Recent advances in the study of hypertrophic and dilated (congestive) cardiomyopathy. Prog Cardiol. 1983;12:225-246.
13. Wilson FM, Miranda QR, Chason JL, Lerner M. Residual pathologic changes following murine coxsackie A and B myocarditis. Am J Pathol. 1969;55:253-265.
14. Shioi T, Matsumori A, Sasayama S. Persistent expression of cytokine in the chronic stage of viral myocarditis in mice. Circulation. 1996;94: 2930-2937.
15. Matsumori A. Molecular and immune mechanisms in the pathogenesis of cardiomyopathy: role of viruses, cytokines, and nitric oxide. Jpn Circ J. 1997;61:275-291.
16. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236-241.
17. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J. 1994;72:561-566.
18. Katz SD, Rao R, Berman JW, Schwarz M, Demopoulos L, Bijou R, LeJemtel TH. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure: relation to nitric oxide-dependent vasodilation in the forearm circulation. Circulation. 1994;90:12-16.
19. Beckman JS. The double-edged role of nitric oxide in brain function and superoxide-mediated injury. J Dev Physiol. 1991;15:53-59.
20. Martino TA, Liu P, Petric M, Sole MJ. Enteroviral myocarditis and dilated cardiomyopathy: a review of clinical and experimental studies. In: Rotbart HA, ed. Human Enterovirus Infections. Washington, DC: American Society for Microbiology; 1995;291-351.
21. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A. 1990;87:1620-1624.
22. Ishiyama S, Hiroe M, Nishikawa T, Abe S, Shimojo T, Ito H, Ozasa S, Yamakawa K, Matsuzaki M, Mohammed MU, Nakazawa H, Kasajima T, Marumo F. Nitric oxide contributes to the progression of myocardial damage in experimental autoimmune myocarditis in rats. Circulation. 1997;95:489-496.
23. Lodge PA, Herzum M, Olszewski J, Huber SA. Coxsackievirus B-3 myocarditis: acute and chronic forms of the disease caused by different immunopathogenic mechanisms. Am J Pathol. 1987;128:455-463.
24. Godeny EK, Gauntt CJ. Involvement of natural killer cells in coxsackievirus B3 viral-induced myocarditis. J Immunol. 1986;137:1695-1702.
25. Godeny EK, Gauntt CJ. Interferon and natural killer cell activity in coxsackie virus B3-induced murine myocarditis. Eur Heart J. 1987; 8(suppl ):433-435.
26. Godeny EK, Gauntt CJ. Murine natural killer cells limit coxsackie virus B3 replication. J Immunol. 1987;139:913-918.
27. Seko Y, Shinkai Y, Kawasaki A, Yagita H, Okumura K, Yazaki Y. Evidence of perforin-mediated cardiac myocyte injury in acute murine myocarditis caused by coxsackie virus B3. J Pathol. 1993;170:53-58.
28. Young LHY, Joag SV, Zheng LM, Lee CP, Lee YS, Young JDE. Perforin-mediated myocardial damage in acute myocarditis. Lancet. 1990;336:1019-1021.
29. Matsumori A, Kawai C. Experimental animal models of viral myocarditis. Eur Heart J. 1987;8(suppl J):383-388.
30. Matsumori A, Kawai C, Crumpacker CS, Abelmann WH. Pathogenesis and preventive and therapeutic trials in an animal model of dilated cardiomyopathy induced by a virus. Jpn Circ J. 1987;51:661-664.
31. Matsumori A, Okada I, Kawai C, Crumpacker CS, Abelmann WH. Animal models for therapeutic trials of viral myocarditis: effect of ribavirin and alpha interferon on coxsackievirus B3 and encephalomyocarditis virus myocarditis. In: Schultheiss H-P, ed. New Concepts in Viral Heart Disease. Berlin, Germany: Springer-Verlag: 1988:377-384.
32. Matsumori A, Tomioka N, Kawai C. Protective effect of recombinant alpha interferon on coxsackievirus B3 myocarditis in mice. Am Heart J. 1988;115:1229-1232.
33. Lutton CW, Gauntt CJ. Ameliorating effect of IFN-β and anti-IFN-β on coxsackievirus B3-induced myocarditis in mice. J Interferon Res. 1985; 5:137-146.
34. Ungureanu-Longrois D, Billigand J-L, Simmons WW, Okada I, Kobzik L, Lowenstein CJ, Kunkel SL, Michel T, Kelly RA, Smith TW. Induction of nitric oxide synthase activity by cytokines in ventricular myocytes is necessary but not sufficient to decrease contractile responsiveness to β-adrenergic agonists. Circ Res. 1995;77:494-502.
35. Ungureanu-Longrois D, Billigand J-L, Okada I, Simmons WW, Kobzik L, Lowenstein CJ, Kunkel SL, Michel T, Kelly RA, Smith TW. Cardiac responsiveness of ventricular myocytes to isoproterenol is regulated by induction of nitric oxide synthase activity in cardiac microvascular endothelial cells in heterotypic primary culture. Circ Res. 1995;77: 486-493.
36. Tomioka N, Kishimoto C, Matsumori A, Kawai C. Effects of prednisolone on acute viral myocarditis in mice. J Am Coll Cardiol. 1986; 7:868-872.
37. Kawai C, Takatsu T. Clinical and experimental studies on cardiomyopathy. N Engl J Med. 1975;293:592-597.
38. Kishimoto C, Kuribayashi K, Masuda T, Tomioka N, Kawai C. Immunologic behavior of lymphocytes in experimental viral myocarditis: significance of T lymphocytes in the severity of myocarditis and silent myocarditis in BALB/c-nu/nu mice. Circulation. 1985;71:1247-1254.
39. + (immature T) subsets in the development of myocarditis. Circulation. 1987;61:715-725.
40. Huber SA, Lodge PA. Coxsackievirus B-3 myocarditis in Balb/c mice: evidence for autoimmunity to myocyte antigens. Am J Pathol. 1984; 116:21-29.
41. Seko Y, Tsuchimochi H, Nakamura T, Okumura K, Naito S, Imataka K, Fujii J, Takaku F, Yazaki Y. Expression of major histocompatibility complex class I antigen in murine ventricular myocytes infected with coxsackievirus B3. Circ Res. 1990;67:360-367.
42. Seko Y, Shinkai Y, Kawasaki A, Yagita H, Okumura K, Takaku F, Yazaki Y. Expression of perform in infiltrating cells in murine hearts with acute myocarditis caused by coxsackievirus B3. Circulation. 1991; 84:788-795.
43. Seko Y, Yagita H, Okumura K, Yazaki Y. T-cell receptor Vβ gene expression in infiltrating cells in murine hearts with acute myocarditis caused by coxsackievirus B3. Circulation. 1994;89:2170-2175.
44. Seko Y, Yoshifumi E, Yagita H, Okumura K, Yazaki Y. Restricted usage of T-cell receptor Vα genes in infiltrating cells in murine hearts with acute myocarditis caused by coxsackie virus B3. J Pathol. 1996; 178:330-334.
45. Seko Y, Ishiyama S, Nishikawa T, Kasajima T, Hiroe M, Kagawa N, Osada K, Suzuki S, Yagita H, Okuda K, Yazaki Y. Restricted usage of T cell receptor Vα-Vβ genes in infiltrating cells in the hearts of patients with acute myocarditis and dilated cardiomyopathy. J Clin Invest. 1995; 96:1035-1041.
46. Seko Y, Matsuda H, Kato K, Hashimoto Y, Yagita H, Okumura K, Yazaki Y. Expression of intercellular adhesion molecule-1 in murine hearts with acute myocarditis caused by coxsackievirus B3. J Clin Invest. 1993;91:1327-1336.
47. Freeman GJ, Freedman AS, Segil JM, Lee G, Whitman JF, Nadler LM. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol. 1989;143:2714-2722.
48. Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lanler LL, Somoza C. B70 antigen is a second ligand for CTLA-4 and CD28. Nature. 1993;366:76-79.
49. Woodruff JF, Woodruff JJ. Involvement of T lymphocytes in the pathogenesis of coxsackie virus B3 heart disease. J Immunol. 1974;113: 1726-1734.
50. Kishimoto C, Abelmann WH. Monoclonal antibody therapy for prevention of acute coxsackievirus B3 myocarditis in mice. Circulation. 1989;79:1300-1308.
51. Huber SA, Job LP, Woodruff JF. Lysis of infected myofibers by coxsackievirus B-3-immune T lymphocytes. Am J Pathol. 1980;98: 681-694.
52. Martino TA, Liu P, Sole MJ. Viral infection and the pathogenesis of dilated cardiomyopathy. Circ Res. 1994;74:182-188.
53. Cronin ME, Love LA, Miller FW, McClintock PR, Plotz PH. The natural history of encephalomyocarditis virus-induced myositis and myocarditis in mice: viral persistence demonstrated by in situ hybridization. J Exp Med. 1988;168:1639-1648.
54. Klingel K, Hohenadl C, Canu A, Albrecht M, Seemann M, Mall G, Kandolf R. Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replication, tissue damage, and inflammation. Proc Natl Acad Sci U S A. 1992;89:314-318.
55. Jin O, Sole MJ, Butany JW, Chia WK, McLaughlin PR, Liu P, Liew CC. Detection of enterovirus RNA in myocardial biopsies from patients with myocarditis and cardiomyopathy using gene amplification by polymerase chain reaction. Circulation. 1990;82:8-16.
56. Weiss LM, Movahed LA, Billingham ME, Cleary ML. Detection of coxsackievirus B3 RNA in myocardial tissues by the polymerase chain reaction. Am J Pathol. 1991;138:497-503.
57. Kyu B-s, Matsumori A, Sato Y, Okada I, Chapman NM, Tracy S. Cardiac persistence of cardioviral RNA detected by polymerase chain reaction in a murine model of dilated cardiomyopathy. Circulation. 1992;86:522-530.
58. Wee L, Liu P, Penn L, Butany JW, McLaughlin PR, Sole MJ, Liew CC. Persistence of viral genome into late stage of murine myocarditis detected by polymerase chain reaction. Circulation. 1992;86: 1605-1614.
59. Jin O, Sole MJ, Butany JW, Chia WK, McLaughlin PR, Liu P, Liew CC. Detection of enterovirus RNA in myocardial biopsies from patients with myocarditis and cardiomyopathy using gene amplification by polymerase chain reaction. Circulation. 1990;82:8-16.
60. Weiss LM, Movahed LA, Billingham ME, Cleary ML. Detection of coxsackievirus B3 RNA in myocardial tissue by the polymerase chain reaction. Am J Pathol. 1991;138:497-503.
61. Chow LH, Gauntt CJ, McManus BM. Differential effects of myocarditic variants of coxsackievirus B3 in inbred mice. Lab Invest. 1991;64: 55-64.
62. Giacca M, Severini GM, Mestroni L, Salvi A, Lardieri G, Falaschi A, Camerini F. Low frequency of detection by nested polymerase chain reaction of enterovirus ribonucleic acid in endomyocardial tissue in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994;24:1033-1040.
63. Matsumori A, Matoba Y, Sasayama S. Dilated cardiomyopathy associated with hepatitis C virus infection. Circulation. 1995;92:2519-2525.
64. Okabe M, Fukuda K, Arakawa K, Kikuchi M. Chronic variant of myocarditis associated with hepatitis C virus infection. Circulation. 1997;96:22-24.
65. Neu N, Rose NR, Beisel KW, Herskowitz A, Curri-Glass G, Craig SW. Cardiac myosin induces myocarditis in genetically predisposed mice. J Immunol. 1987;139:3630-3636.
66. Kodama M, Hanawa H, Saeki M, Hosono H, Inomata T, Suzuki K, Shibata A. Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. Circ Res. 1994;75:278-284.
67. Wolfgram LL, Beisel KW, Rose NR. Heart-specific autoantibodies following murine coxsackievirus B3 myocarditis. J Exp Med. 1985;161: 1112-1121.
68. Cunningham MW, Antone SM, Gulizia JM, McManus BM, Feschetti VA, Gauntt CJ. Cytotoxic and viral neutralizing antibodies crossreact with streptococcal M protein, enteroviruses, and human cardiac myosin. Proc Natl Acad Sci U S A. 1992;89:1320-1324.
69. Gauntt CJ, Higdon AL, Arizpe HM, Tamayo MR, Crawley R, Henkel RD, Pereira MEA, Tracy SM, Cunningham MW. Epitopes shared between coxsackievirus B3 (CVB3) and normal heart tissue contribute to CVB3-induced murine myocarditis. Clin Immunol Immunopathol. 1993;68:129-134.
70. Inomata T, Hanawa H, Miyanishi T, Yajima E, Nakayama S, Maita T, Kodama M, Izumi T, Shibata A, Abo T. Localization of porcine cardiac myosin epitopes that induce experimental autoimmune myocarditis. Circ Res. 1995;76:726-733.
71. Pummerer CL, Luze K, Grassl G, Bachmaier K, Offner F, Burrell SK, Lenz DM, Zamborelli TJ, Penninger JM, Neu N. Identification of cardiac myosin peptides capable of inducing autoimmune myocarditis in BALB/c mice. J Clin Invest. 1996;97:2057-2062.
72. James TN. Normal and abnormal consequences of apoptosis in the human heart: from postnatal morphogenesis to paroxysmal arrhythmias. Circulation. 1994;90:556-573.
73. James TN, Nichols MM, Sapire DW, DiPatre PL, Lopez SM. Complete heart block and fatal right ventricular failure in an infant. Circulation. 1996;93:1588-1600.
74. James TN, St Martin E, Willis PW III, Lohr TO. Apoptosis as a possible cause of gradual development of complete heart block and fatal arrhythmias associated with absence of the AV node, sinus node, and internodal pathways. Circulation. 1996;93:1424-1438.
75. Misao J, Hayakawa Y, Ohno M, Kato S, Fujiwara T, Fujiwara H. Expression of bcl-2 protein, an inhibitor of apoptosis, and Bax, an accelerator of apoptosis, in ventricular myocytes of human hearts with myocardial infarction. Circulation. 1996;94:1506-1512.
76. Isner JM, Kearney M, Bostman S, Passeri J. Apoptosis in human atherosclerosis and restenosis. Circulation. 1995;91:2703-2711.
77. Tanaka M, Ito H, Adachi S, Akimoto H, Nishikawa T, Kasajima T, Marumo F, Hiroe M. Hypoxia induces apoptosis with enhanced expression of Fas antigen messenger RNA in cultured neonatal rat cardiomyocytes. Circ Res. 1994;75:426-433.
78. Gougeon M-L, Montagnier L. Apoptosis in AIDS. Science. 1993;260: 1269-1270.
79. + T lymphocytes in acute infectious mononucleosis supporting their susceptibility to programmed cell death. Blood. 1993;82:521-527.
80. Rao I, Debbas M, Sabbatini P, Hockenberry D, Korsmeyer S, White E. The adenovirus EIA proteins induce apoptosis, which is inhibited by the EIB 19-kDa and Bcl-2 proteins. Proc Natl Acad Sci U S A. 1992;89: 7742-7746.
81. Sole MJ, Liu P. Viral myocarditis: a paradigm for understanding the pathogenesis and treatment of dilated cardiomyopathy. J Am Coll Cardiol. 1993;22(suppl A):99A-105A.
82. Yamada T, Matsumori A, Okada I, Tominaga M, Kawai C. The effect of α1-blocker, bunazosin, on a murine model of congestive heart failure induced by viral myocarditis. Jpn Circ J. 1992;56:1138-1145.
83. Tominaga M, Matsumori A, Okada I, Yamada T, Kawai C. β-Blocker treatment of dilated cardiomyopathy: beneficial effect of carteolol in mice. Circulation. 1991;83:2121-2028.
84. Dong R, Liu P, Wee L, Butany J, Sole MJ. Verapamil ameliorates the clinical and pathological course of murine myocarditis. J Clin Invest. 1992;90:2022-2030.
85. Rezkalla S, Kloner RA, Khatib G, Khatib R. Beneficial effects of captopril in acute coxsackievirus B3 murine myocarditis. Circulation. 1990;81:1039-1046.
86. Matsumori A, Suzuki H, Kawai C. Beneficial effects of captopril in coxsackievirus myocarditis. Circulation. 1990;82:1882-1883. Letter.
87. Factor SM, Sonnenblick EH. The pathogenesis of clinical and experimental congestive cardiomyopathies: recent concepts. Prog Cardiovasc Dis. 1985;27:395-420.
88. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Weitheimer JH, Cropp AB, DeMets DL, for the Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 1996;335:1107-1114.
89. Matsumori A, Ono K, Nishio R, Nose Y, Sasayama S. Amiodarone inhibits production of tumor necrosis factor-α by human mononuclear cells: a possible mechanism for its effect in heart failure. Circulation. 1997;96:1386-1389.
90. Matsumori A, Wang H, Abelmann WH, Crumpacker CS. Treatment of viral myocarditis with ribavirin in an animal preparation. Circulation. 1985;71:834-839.
91. Matsumori A, Crumpacker CS, Abelmann WH. Prevention of viral myocarditis with recombinant human leukocyte interferon α A/D in a murine model. J Am Coll Cardiol. 1987;9:1320-1325.
92. Claman HN. Corticosteroids and lymphoid cells. N Engl J Med. 1972; 287:388-397.
93. Monrad ES, Matsumori A, Murphy JC, Fox JG, Crumpacker CS, Abelmann WH. Therapy with cyclosporine in experimental murine myocarditis with encephalomyocarditis virus. Circulation. 1986;73: 1058-1064.
94. Kishimoto C, Abelmann WH. Absence of effects of cyclosporine on myocardial lymphocyte subsets in coxsackievirus B3 myocarditis in the aviremic stage. Circ Res. 1989;65:934-945.
95. Hiraoka Y, Kishimoto C, Kurokawa M, Ochiai H, Sasayama S. The effects of FK-506, a novel and potent immunosuppressant, upon murine coxsackievirus B3 myocarditis. J Pharmacol Exp Ther. 1991;260: 1386-1391.
96. McCormick S, Dowler K, Armstrong JA, Hsiung GD. Cyclophosphamide immunosuppression during lymphotropic herpes-virus infection in the guinea pig model: a histopathologic and virologic study. Am J Pathol. 1987;127:538-548.
97. Kishimoto C, Thorp KA, Abelmann WH. Immunosuppression with high doses of cyclophosphamide reduces the severity of myocarditis but increases the mortality in murine coxsackievirus B3 myocarditis. Circulation. 1990;82:982-989.
98. Reyes M, Lerner AM. Coxsackievirus myocarditis: with special reference to acute and chronic effects. Prog Cardiovasc Dis. 1985;27: 373-394.
99. Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, Moon TE, and the Myocarditis Treatment Trial Investigators. A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med. 1995;333:269-275.
100. Takada H, Kishimoto C, Hiraoka Y. Therapy with immunoglobulin suppresses myocarditis in a murine coxsackievirus B3 model: antiviral and anti-inflammatory effects. Circulation. 1995;92:1604-1611.
101. Drucker NA, Colan SD, Lewis AB, Beiser AS, Wessel DL, Takahashi M, Baker AL, Perez-Atayde AR, Newburger JW. γ-Globulin treatment of acute myocarditis in the pediatric population. Circulation. 1994;89: 252-257.
102. Newburger JW, Sanders SP, Burns JC, Parness IA, Beiser AS, Colan SD. Left ventricular contractility and functions in Kawasaki syndrome: effect of intravenous gamma globulin. Circulation. 1989;79:1237-1246.
103. Gudvangen RJ, Duffey PS, Paque RE, Gauntt CJ. Levamisole exacerbates coxsackievirus B3-induced murine myocarditis. Infect Immun. 1983;41:1157-1165.
104. Huber SA, Polgar J, Schultheiss P, Schwimmbeck P. Augmentation of pathogenesis of coxsackievirus B3 infection in mice by exogenous administration of IL-1 and IL-2. J Virol. 1994;68:195-206.
105. Matsumori A, Yamada T, Kawai C. Immunomodulating therapy in viral myocarditis: effects of tumor necrosis factor, interleukin 2 and anti-interleukin-2 receptor antibody in an animal model. Eur Heart J. 1991; 12(suppl D):203-205.
106. DuBois JS, Udelson JE, Atkins MB. Severe reversible global and regional ventricular dysfunction associated with high-dose interleukin-2 immunotherapy. J Immunother. 1995;18:119-123.
107. Seko Y, Takahashi N, Azuma M, Yagita H, Okumura K, Yazaki Y. Effects on in vivo administration of anti-B7-1/B7-2 monoclonal antibodies on murine acute myocarditis caused by coxsackievirus B3. Circ Res. 1998;82:613-618.